‘No-Deal’ Brexit: UK Would Keep Rules on Patents, SPCs & Parallel Trade
Executive Summary
The latest “technical notices” from the government say that there will be no material change to the rules on intellectual property protections and compulsory licensing if the UK leaves the EU without a deal, and that the government also intends to continue allowing parallel imports of medicines from Europe to the UK.
You may also be interested in...
BIA ‘Reassured’ On Post-Brexit SPC Regime But Data Exclusivity Concerns Remain
The government has said it is prepared to discuss the terms of supplementary protection certificates under a UK-only regime if there is a no-deal Brexit, but concerns also linger over the start dates for regulatory data protection.
Parallel Trade Adds Up As Abacus Prepares IPO
With revenues from its parallel trade business climbing 50% year-on-year since 2015, Denmark's Abacus is to seek a listing in Germany to help it keep up with demand.
UK's No-Deal Brexit Plans Revealed For Pharma Sector
The UK government has published “technical notices” explaining what would change in the drug regulatory arena in the event of a no-deal Brexit, and what stakeholders need to do to prepare. Companies will be expected to stockpile medicines in the immediate run-up to the UK's departure from the EU.